How has been the historical performance of Vista Pharma.?

Answer:The historical performance of Vista Pharma shows significant fluctuations in key financial metrics over the years.

Breakdown:
Vista Pharma's net sales have seen a decline from 31.07 Cr in Mar'19 to 10.07 Cr in Mar'25, with a notable drop to 1.00 Cr in Mar'23. The total operating income followed a similar trend, decreasing from 31.07 Cr in Mar'19 to 10.07 Cr in Mar'25. The company's total expenditure, excluding depreciation, increased from 29.84 Cr in Mar'19 to 14.10 Cr in Mar'25, indicating rising costs despite lower revenues. Operating profit (PBDIT) has been negative since Mar'20, worsening from -1.04 Cr in Mar'22 to -3.59 Cr in Mar'25. Profit before tax also remained negative, reaching -5.29 Cr in Mar'25, while profit after tax was -4.65 Cr in the same period. The company's total assets increased from 50.74 Cr in Mar'20 to 55.92 Cr in Mar'25, driven by a rise in shareholder's funds from 29.64 Cr to 45.42 Cr. However, total debt decreased from 15.47 Cr in Mar'20 to 7.40 Cr in Mar'25, reflecting a reduction in long-term borrowings. Cash flow from operating activities has been negative, with -6.00 Cr reported in Mar'25, while cash flow from financing activities improved to 8.00 Cr in the same year. Overall, Vista Pharma's financial performance indicates challenges with profitability and operational efficiency, despite some improvements in capital structure.